When to Use Initial Triple Therapy in #COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment

Triple therapy versus dual therapy for chronic pulmonary obstructive disease (COPD) can reduce symptoms, limit the risk of acute exacerbations (AEs) as well as improve lung function. Currently, studies that feature clinically important deterioration (CID) as a composite endpoint to assess the need for treatment intensification for patients maintained on dual therapy remained to be scarce. Patients and Methods: This study is a retrospective analysis … Continue reading When to Use Initial Triple Therapy in #COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment

Rate This

A Neutralizing Monoclonal #Antibody for Hospitalized Patients with Covid-19

LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19 METHODS In this platform trial of therapeutic agents, we randomly assigned hospitalized patients who had Covid-19 without end-organ failure … Continue reading A Neutralizing Monoclonal #Antibody for Hospitalized Patients with Covid-19

Rate This